The IMI2 Paincare Consortium is composed of 40 participants from 14 countries; 6 are EFPIA (European Federation of Pharmaceutical Industries and Associations) participants with strong traditions in pain research and development, 23 are internationally renowned academic and clinical institutions, 5 are specialist SMEs with cutting-edge technologies, 3 are patient organizations and 3 are professional pain/anesthesia societies.
The Consortium addresses three important topics:
- Patient reported outcome measures to improve management of acute and chronic pain (PROMPT);
- Pharmacological validation of functional pain biomarkers in healthy subjects and animals (BioPain);
- Improving translation in chronic pelvic pain (TRiPP).